See highlights from GHTC's 2022 Innovating for Impact Awards

Search the GHTC website

News & Insights

News & Insights

Latest news

Check out the latest news and announcements from GHTC.

GHTC
December 7, 2022

Dr. Anthony Fauci, Senators Sherrod Brown and Todd Young, and developers of pretomanid and the BPaL regimen honored at GHTC’s Innovating for Impact Awards

At GHTC's sixth annual Innovating for Impact Awards, Senators Sherrod Brown and Todd Young received Congressional Champion Awards, the developers of pretomanid and the BPaL regimen received the Partnership Award, and Dr. Anthony Fauci received the first-ever Lifetime of Service Award. 

Read time:
The Global Health Technologies Coalition (GHTC) yesterday honored Dr. Anthony Fauci, Senator Sherrod Brown (D-OH), and Senator Todd Young (R-IN) for their leadership in supporting global health research and development (R&D) at the 2022 Innovating for Impact Awards, an annual initiative recognizing US policymakers and partnerships catalyzing global health innovation. Additionally, GHTC recognized the partnership, led by TB Alliance, that developed the breakthrough technology pretomanid and the BPaL regimen—a shortened, simplified, and highly effective therapy for drug-resistant tuberculosis (DR-TB). This year's awards also coincided with GHTC's 15th anniversary—a period over which the global health community has seen incredible innovation and progress.Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) and the chief medical advisor to the President was honored with Innovating for Impact’s first-ever Lifetime of Service Award for his extensive and wide-ranging contributions to advancing global health and global health research, including groundbreaking contributions to HIV/AIDS research that inform our understanding of the disease to this day, inspiring the creation of the US President’s Emergency Plan for AIDS Relief (PEPFAR), leading NIAID for decades, confronting COVID-19 and previously generation-defining health threats, and advising no fewer than seven US presidents. Dr. Fauci’s remarks set the tone for the evening, as he acknowledged the power of partnership in tackling the global health challenges and what can be accomplished with effective collaborations. To underscore this, Dr. Fauci referenced the R&D response to the Covid-19 pandemic, noting "What we're experiencing now with Covid, I think is another really good example of how important it is for groups getting together in a coalition type fashion. And I'm talking about what was accomplished in an extraordinary manner with the development of vaccines for Covid-19. I mean, this could not have been done by any individual component of the coalitions."Senator Sherrod Brown was honored with a Congressional Champion Award, celebrating his contributions to global health research policy, which include spearheading legislation that led to the Tropical Disease Priority Review Voucher Program that has incentivized the development of new, lifesaving global health technologies for more than 25 neglected diseases; encouraging President Obama to release the National Action Plan for Combating Multidrug-Resistant Tuberculosis; and sponsoring the Comprehensive TB Elimination and End Neglected Tropical Diseases Acts. Senator Brown highlighted the tremendous impact commitments to public health have on the world and the key role the advocacy community plays in marshaling political support for global health innovation, “Public health lifts all boats…You do things right, everybody in society gains. And we all live longer, because of the emphasis on public health…We've made huge, huge progress as these awards tonight show, as your activism shows."GHTC also recognized Senator Todd Young with a Congressional Champion Award. Senator Young has supported global health R&D through many pieces of legislation. He co-authored the Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act to bolster the development of antimicrobial innovations for deadly pathogens and infections, introduced the End TB Now Act to support the development of new tools to combat tuberculosis (TB) through the United States Agency of International Development (USAID), and championed a call for innovative tools to end preventable child and maternal deaths through the introduction of the Reach Every Mother and Child Act.In recorded remarks, Senator Young reiterated his commitment to global health technology innovation, stating, “I continue to support robust funding for medical research because sustained investments have enabled critical biomedical innovation and discovery and help to find new tar new treatments and cures fo global diseases.”GHTC presented the Partnership Award to TB Alliance for the development of pretomanid and the BPaL regimen—an innovative treatment for drug-resistant DR-TB. Dr. Mel Spigelman, president and chief executive officer of TB Alliance, accepted the award on behalf of the partners, and joining him on stage were Natasha Bilimoria, deputy assistant administrator of USAID, and Barbara Laughon, senior scientist for TB Drug Development Partnerships at the US National Institutes for Health, representing two key partners in the development of pretomanid. Pretomanid is the first TB drug developed by a nonprofit organization. Pretomanid is part of the three-drug “BPaL” regimen. This innovative new therapy reduces the time needed to treat DR-TB from as long as 18 months or longer to 6 months and the number of pills comprising treatment by nearly 95 percent, all while significantly improving cure rates and toxicity profiles compared to the previous standards of care.In a video exploring the development, benefits, and impacts of pretomanid and the BPaL regimen, Jayshree Rampiar, a DR-TB survivor treated with the regimen, noted, “Before [treatment] had a lot of side effects, and the medication I’m taking now has less. I feel that my future is looking bright, and we can beat TB!”GHTC’s executive director, Jamie Bay Nishi closed the event by reminding us that while there is so much excellent and encouraging progress to celebrate, we still do not have all the tools needed to fully overcome the formidable global health challenges now and on the horizon. Thus, we must continue to strengthen our efforts to ensure more transformative innovations are developed and reach those around the world who need them. The Innovating for Impact Awards will continue to celebrate US commitment to global health R&D and honor the multisector partnerships and policymakers that drive the development of lifesaving technologies for global health challenges both old and new. We thank all those who support global health innovation. As Senator Sherrod Brown noted in his remarks, “None of this [progress] would have happened without the activism of so many of you around the world!”Continue to follow the discussion—and celebration—on Twitter at the hashtag #Innovate4Health.
US Department of State/Ron Przysucha
December 7, 2022

GHTC signs onto letter ahead of US-Africa Leaders Summit calling on critical actions to address the impacts of COVID-19

GHTC signed onto a letter led by Pandemic Action Network ahead of the US-Africa Leaders Summit calling for critical actions to address the impacts of COVID-19.

Read time: 3 minutes / PDF link
  • Annoucements
  • In the media
  • Advocacy actions
VIEW ALL NEWS

Latest from the Breakthroughs Blog

Read stories about bright ideas and bold innovations in global health.

Governor Tom Wolf
November 15, 2021

Research Roundup: Ebola vaccine human trials, a preventive antibody cocktail, and injectable antibody treatment

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Written by Anna Kovacevich / GHTC
Read time:
Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. A clinical trial is launching to evaluate a new Ebola vaccine that could protect against multiple species of the virus. While effective vaccines against Ebola have been developed in recent years, they have been approved for only one of the four species of the Ebola virus—the Zaire species, which is responsible for many outbreaks and has the highest mortality rate. Researchers at the University of Oxford are now starting human trials of a new vaccine designed to protect against the Sudan species in addition to the Zaire species, which together have caused almost all of the Ebola outbreaks and deaths. The vaccine is based on the same underlying technology used for the Oxford-AstraZeneca COVID-19 vaccine.Regeneron’s antibody cocktail reduced the risk of COVID-19 infection by 81.6 percent over a period of two to eight months, according to phase 3 trial results announced last week. Previously reported results from the trial had shown REGEN-COV to reduce risk of infection during the first month after administration; the new results demonstrate potential for the drug to provide more long-lasting preventive immunity, which could be an important tool for those who do not respond to COVID-19 vaccines, including people who are immunocompromised. The antibody cocktail is currently authorized in the United States and European Union to treat non-hospitalized patients who are already infected and at high risk of severe illness and in certain cases as a post-exposure prophylaxis.GlaxoSmithKline (GSK) and Vir Biotechnology announced on Friday that their COVID-19 antibody treatment, sotrovimab, works as well when given as a shot in the arm as when administered via standard infusion. Intramuscular injection could offer additional convenience for delivery of the treatment, as it can be performed by family doctors in non-hospital settings. Sotrovimab is authorized for emergency use in the United States to mitigate progression of mild and moderate cases of COVID-19, and the European Medicines Agency has greenlit its use by member states, though EU-wide approval is still outstanding. GSK plans to speak to global regulators, including the US Food and Drug Administration, about approval for the new method of administration.
Paul Kagame/Flickr
November 10, 2021

Missed opportunity: Final G20 meetings deliver good rhetoric but no action

Written by Philip Kenol / GHTC
Read time:
With the world still reeling from the pandemic and global inequities more exposed than ever when it comes to access to medical countermeasures and response capabilities, all eyes were glued on G20 leaders in Rome last week. This G20 heads of state meeting was supposed to be a key global moment for shaping effective, innovative, and equitable responses toward a new post-pandemic global health architecture, but world leaders failed to come together and deliver the necessary action to end the historic crisis still unfolding or create the structures to prepare for the next one. The meeting did offer a small glimmer of hope: research and innovation was firmly anchored as a core tenet of leaders’ strategies to address a myriad of global health challenges, whether COVID-19-related or focused on enduring health threats. While this very much feels like the G20 missed its opportunity, hope remains that the international community can utilize other upcoming forums to take up the torch.  Missing the mark As G20 leaders got together to hammer out agreements to address both current and future health challenges, expectations were high, as many global health advocates hoped the group would start taking concrete steps to act on the numerous initiatives and recommendations from the various review processes this past year. Unfortunately, the global health community was left disappointed, as G20 leaders failed to step up to the plate, providing little by way of concrete pledges, funding, or specific road maps on how to turn their words into action. While countries agreed to a target to vaccinate 40 percent of the world by the end of the year and 70 percent by the middle of 2022, they offered no concrete plans to achieve that goal and failed to make good on their earlier dose promises to COVAX by confirming actual delivery dates. Under current projections, close to 80 countries won’t hit that 40 percent mark by year’s end and would struggle to hit the target in the first quarter of 2022.  Funding also remains a concern, as G20 nations made no new commitments to help address the US$15.9 billion shortfall in monies needed by the Access to COVID-19 Tools Accelerator to accelerate the rollout of tests, treatments, and vaccines, as well as the continued investment needed in innovation to address variants as well as second-generation medical countermeasures that can be more easily deployed. There were also expectations that the G20 would agree to some framework for the creation of a financial intermediary fund for pandemic preparedness, a mechanism that would provide countries with financing to address their long-term preparedness capacity strengthening needs, including potential investments in surveillance, laboratory, clinical trial, and manufacturing infrastructure. However, the G20 didn’t jump at the opportunity to move this initiative forward at the summit, choosing instead to set up a finance-health task force to consider a potential financing facility, creating yet another process.  Silver lining on research and development Despite not spelling out major commitments, the G20 leaders did include several high-level pledges related to research and development (R&D) and broadly acknowledged that research and innovation are important cornerstones of pandemic preparedness and response capacity writ large. It is rare that the G20 leaders’ communique makes direct mention of R&D, so seeing that language included in the final document is remarkable in and of itself. What stands out in the declaration is a pledge by G20 countries to support science to shorten the cycle for the development of safe and effective vaccines, therapeutics, and diagnostics from 300 to 100 days following their identification. While this ambitious target was not supported directly by specific commitments, it does provide a principles framework for future discussions on R&D coordination and capacity strengthening. G20 leaders also had strong rhetoric on strengthening supply chains and manufacturing capacity in the long term, highlighting the need to support mRNA hubs in low- and middle-income countries in particular. Finally, it was also good to see explicit callouts underscoring the need to sustain investments in malaria, tuberculosis, and HIV/AIDS and tackle the growing threat of antimicrobial resistance.  Who will pick up the torch? While this year’s G7 and G20 processes did not lead to the kind of concrete commitments advocates were hoping for, there are still a few summits and milestones in the coming months that could help cement follow-through action to meet global vaccination targets, fully resource the global COVID-19 response including ongoing R&D needs, and enhance transparency around the global supply and delivery of COVID-19-related medical countermeasures. Today, US Secretary of State Antony Blinken will host a meeting with foreign ministers from several countries to discuss commitments to the global COVID-19 response in follow-up to the Global COVID-19 Summit in September. There are also the ongoing discussions being held by member states in the lead-up to the upcoming special session of the World Health Organization on how to strengthen the agency’s health preparedness capabilities, including a potential new framework convention or pandemic treaty. These deliberations have considered a number of changes to the global health security architecture, including developing and reforming governance and coordination mechanisms for R&D. The pressure is now on these forums to deliver solutions to the broad set of challenges that the G20 Ministerial didn’t deliver and to build on the strong rhetoric on R&D to create a fit-for-purpose global health system that provides true equitable access to the health tools the world needs. 
USAID/Des Syafrizal
November 8, 2021

Research Roundup: A WHO vaccine approval, first oral antiviral COVID-19 treatment, and Pfizer's COVID-19 pill

Written by Anna Kovacevich / GHTC
Read time:
Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. The World Health Organization (WHO) last week issued an emergency use listing for the Covaxin COVID-19 vaccine, developed by Indian pharmaceutical company Bharat Biotech, making it the eighth vaccine to receive WHO authorization. Covaxin, which is formulated from an inactivated SARS-CoV-2 antigen, was found to be 78 percent effective against COVID-19 of any severity 14 or more days after the second dose. WHO review groups determined the vaccine meets standards for protection against COVID-19, with benefits far outweighing the risks, and recommended it be used in two doses with a dose interval of four weeks for people 18 and above. The WHO approval makes Covaxin eligible for distribution through the COVAX vaccine-sharing facility, and the vaccine’s easy storage requirements make it especially suited for global distribution.Merck’s oral COVID-19 treatment, molnupiravir, received approval from its first regulatory body Thursday when the UK Medicines and Healthcare products Regulatory Agency authorized its use for individuals with mild to moderate COVID-19 and at least one risk factor for developing severe illness. The treatment—the first antiviral medication for COVID-19 that can be taken as a pill rather than injected or given intravenously—cut the risk of hospitalization or death by about half in clinical trials. Given twice a day, starting within five days of symptoms developing to be most effective, the pill targets an enzyme that the virus uses to replicate, preventing it from multiplying—an approach that should make the treatment equally effective against new variants of the virus as it evolves, according to Merck.On Friday, Pfizer released results from a late-stage clinical trial of its antiviral pill to combat COVID-19 showing it to be highly effective at preventing severe illness among at-risk individuals who receive the drug shortly after the onset of symptoms. The pill cut the risk of hospitalization or death by 89 percent when given within three days of exhibiting symptoms, according to data from the trial, which an independent board of experts recommended be stopped early because the drug’s benefit to patients had proved so convincing. Pfizer plans to submit the data as soon as possible to the US Food and Drug Administration to seek authorization for the pill to be used in the United States.
Chris Schwarz/Government of Alberta
November 1, 2021

Research Roundup: A treatment licensing agreement, new ACT-A plan for access, and potential repurposed COVID-19 drug

Written by Anna Kovacevich / GHTC
Read time:
Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email.Pharmaceutical company Merck has announced an agreement to share its license for the oral COVID-19 drug molnupiravir with the United Nations–backed Medicines Patent Pool to expand access to the treatment in more than 100 countries. Molnupiravir, an easy-to-take pill, reduced hospitalizations and deaths by half among higher-risk COVID-19 patients diagnosed with mild to moderate illness in a global clinical trial. The agreement is the first public health license for a COVID-19 treatment or vaccine, allowing the medicine to be produced by all capable manufacturers—once the drug receives regulatory approval—to expand the drug’s availability, widen its manufacturing base, and potentially push down the price. Merck has applied to the US Food and Drug Administration for emergency use authorization, and the European Medicines Agency recently began a rolling review of the drug.The Access to COVID-19 Tools Accelerator (ACT-A) on Thursday launched its new strategic plan outlining a focus on addressing access inequities to tools in underserved areas. Over the next year, ACT-A—a global partnership set up to accelerate the development and delivery of COVID-19 tests, treatments, and vaccines—will aim to support low- and middle-income countries in vaccinating 70 percent of their populations, increasing their testing rates to at least 1 per 1,000 people per day, and treating up to 120 million COVID-19 cases through deployment of existing treatments and enabling access to new therapies. The plan outlines a required budget of $23.4 billion between now and September 2022, including $840 million for research and development.Inexpensive drug fluvoxamine could reduce hospitalization in adults with severe COVID-19, according to research published Wednesday in The Lancet Global Health. The findings, based on a clinical trial in Brazil evaluating high-risk, symptomatic adults who had recently contracted COVID-19, showed participants were less likely to require hospitalization or an extended emergency room stay when given a 100-milligram dose of fluvoxamine twice daily for ten days. Fluvoxamine is commonly prescribed to treat depression and obsessive-compulsive disorder and is known to reduce inflammation, which COVID-19 can cause throughout the body. The study findings, part of the larger TOGETHER Trial aiming to identify repurposed therapies effective against COVID-19 disease progression, have been shared with the World Health Organization and the US National Institutes of Health.
View all blog posts

Upcoming events

Learn more about upcoming events hosted by or featuring GHTC and its members.

September
27
2023

Antibiotic shortages: Causes, consequences, and solutions

GARDP

Virtual Location: Virtual
View
Oct 11, 2023

Launch briefing: New sexual and reproductive health G-FINDER Report

Policy Cures Research

Virtual Location: Virtual
View
Oct 12, 2023

Market interventions to improve access to antibiotics for resistant infections

GARDP

Virtual Location: Virtual
View
Oct 18-22, 2023

ASTMH 2023 Annual Meeting

ASTMH

Location: Chicago, IL
View
  • GHTC event
  • Member event
View all current & past events